Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Society Responds to CMS Questions on Imbruvica as CMS Prepares for Direct Price Negotiations

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

After naming 10 prescription drugs subject to direct government price negotiations, CMS released a series of questions directed at patients and other stakeholders as it prepared for direct price negotiations.  Imbruvica was the only cancer drug in the ten selected drugs.  CLL Society prepared responses related to patient experience, alternative treatments, prescribing information, impact and comparative effectiveness and more. Note the text is drafted as individual Q&As that had to be entered directly into the CMS portal

Download the letter.